期刊
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
卷 18, 期 10, 页码 -出版社
OXFORD UNIV PRESS
DOI: 10.1093/ijnp/pyv042
关键词
Animal studies; biomarkers; clinical samples; imaging; psychiatric disorders
资金
- Australian Research Council [FT100100689]
- BMBF QuantPro grant
- Max Planck Society
- National Health and Medical Research Council [APP1002240]
- International College of Neuropsychopharmacology (CINP)
- MRC [G0701748] Funding Source: UKRI
- Medical Research Council [G0701748] Funding Source: researchfish
- Australian Research Council [FT100100689] Funding Source: Australian Research Council
Background: A think tank sponsored by the Collegium Internationale Neuropsychopharmacologium (CINP) debated the status and prospects of biological markers for psychiatric disorders, focusing on schizophrenia and major depressive disorder. Methods: Discussions covered markers defining and predicting specific disorders or domains of dysfunction, as well as predicting and monitoring medication efficacy. Deliberations included clinically useful and viable biomarkers, why suitable markers are not available, and the need for tightly-controlled sample collection. Results: Different types of biomarkers, appropriate sensitivity, specificity, and broad-based exploitability were discussed. Whilst a number of candidates are in the discovery phases, all will require replication in larger, real-life cohorts. Clinical cost-effectiveness also needs to be established. Conclusions: Since a single measure is unlikely to suffice, multi-modal strategies look more promising, although they bring greater technical and implementation complexities. Identifying reproducible, robust biomarkers will probably require pre-competitive consortia to provide the resources needed to identify, validate, and develop the relevant clinical tests.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据